Received Sep 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 2 | Y014446 | — |
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 1 | — | — |
No additional AE; HCP calling to report 2nd dose of VAQTA administered earlier than recommended for a 11-year-old patient; This spontaneous report was received from other health professional, concerning to a 11-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 09-Jun-2025, the patient was vaccinated with the first dose of Hepatitis A Vaccine, Inactivated (VAQTA), 1 dosage form total, (lot # and expiration date were not reported). On 19-Aug-2025, with the second dose of Hepatitis A Vaccine, Inactivated (VAQTA), (lot #Y014446 has been verified to be valid for this product as a pre-filled syringe, expiration date reported and confirmed as 01-Feb-2026), 0.5 mL, total. Both as prophylaxis. On 19-Aug-2025, since the second dose of VAQTA was administered earlier than recommended for a 11-year-old patient (Inappropriate schedule of product administration). No additional adverse event (No adverse event).